Physician profile
Matthew D Hellmann
NPI 1881853422
$227,783.41
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118K · 2020: $40K · 2021: $50K · 2022: $20K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $111,942.03 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $29,093.64 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $18,830.43 | 2019-2021 | |
| Genentech, INC. | $18,750.00 | 2022 | |
| F. Hoffmann-La Roche Ag | $11,577.98 | 2019-2021 | |
| Astrazeneca Uk Limited | $7,980.00 | 2020-2021 | |
| Regeneron Pharmaceuticals, INC. | $5,895.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $5,080.00 | 2021 | |
| Janssen Global Services, LLC | $4,960.00 | 2021 | |
| Genzyme Corporation | $4,578.00 | 2021 | |
| Eisai INC. | $4,375.00 | 2021 | |
| Daiichi Sankyo INC. | $2,055.00 | 2021 | |
| Eli Lilly and Company | $1,548.07 | 2019-2021 | |
| Astrazeneca Ab | $1,029.24 | 2019 | |
| Celgene Corporation | $77.61 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $11.41 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hellmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.